NEUROGENE INC (NGNE) Stock News

NASDAQ:NGNE - Nasdaq - US64135M1053 - Common Stock - Currency: USD

19.61 -0.1 (-0.51%)

After market: 19.61 0 (0%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

NGNE Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Neurogene Inc.

Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates

10 days ago - By: Benzinga - Mentions: NVAX SRPT QURE MRNA ...

Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction

12 days ago - By: Neurogene Inc.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

22 days ago - By: Benzinga - Mentions: SRPT QURE CAPR NTLA ...

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

2 months ago - By: Neurogene Inc.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Neurogene Inc.

Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome

3 months ago - By: Neurogene Inc.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Yahoo Finance - Mentions: DNUT MDGL FLWS RKT

Short Report: Bears bite into Krispy Kreme after another weak earnings report

3 months ago - By: Neurogene Inc.

Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV

3 months ago - By: Neurogene Inc.

Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates

3 months ago - By: Neurogene Inc.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Neurogene Inc.

Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting

5 months ago - By: Neurogene Inc.

Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome

5 months ago - By: Neurogene Inc.

Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates

6 months ago - By: Neurogene Inc.

Neurogene to Participate in Upcoming Conferences

7 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE

7 months ago - By: Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE

7 months ago - By: Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE

7 months ago - By: Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE

8 months ago - By: Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE

8 months ago - By: Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE

9 months ago - By: Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE